Sonrotoclax, sold under the brand name Beqalzi, is an anti-cancer medication used for the treatment of mantle cell lymphoma. It is a BCL-2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.
Medical uses Sonrotoclax is indicated for the treatment of adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.
Contraindications Sonrotoclax is contraindicated with strong CYP3A inhibitors at initiation and ramp-up phase due to potential increased risk of Tumor lysis syndrome.
Society and culture
Legal status Sonrotoclax was approved for medical use in the United States in May 2026. Sonrotoclax is also approved in China for mantle cell lymphoma, along with CLL/SLL. Sonrotoclax also has a fast track designation by the FDA for Waldenström macroglobulinemia. It additionally has an orphan drug designation by the FDA for Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
Names Sonrotoclax is the international nonproprietary name. Sonrotoclax is sold under the brand name Beqalzi.
References


